# Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

> **NCT02974153** · PHASE3 · COMPLETED · sponsor: **Alder Biopharmaceuticals, Inc.** · enrollment: 1121 (actual)

## Conditions studied

- Migraine Disorders

## Interventions

- **BIOLOGICAL:** ALD403 (Eptinezumab)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02974153
- **Lead sponsor:** Alder Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2017-11
- **Final completion:** 2018-04
- **Target enrollment:** 1121 (ACTUAL)
- **Last updated:** 2020-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02974153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02974153, "Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02974153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*